The potential of electronic nose technology in lung transplantation: a proof of principle
Aim: To explore the potential of electronic nose (eNose) technology in monitoring lung transplant (LTx) recipients, aiming to identify complications such as acute cellular rejection (ACR) and infections early.
Take home message: eNose technology can detect complications after lung transplantation through breath analysis, offering a promising non-invasive alternative for monitoring patient health and identifying issues like rejection and infection early on.
Introduction
Lung transplant recipients are at risk for complications such as acute cellular rejection (ACR), chronic lung allograft dysfunction (CLAD), and infections. Diagnosing these conditions typically requires invasive procedures, which are not ideal for routine monitoring. The study hypothesizes that eNose technology can detect complications early and improve patient outcomes, potentially replacing invasive diagnostic methods.
Methods
The study focused on a 61-year-old female patient who had undergone bilateral lung transplantation 2.4 years prior. Over a three-month period, the patient underwent nine follow-up visits at the outpatient clinic, where exhaled breath was analyzed using the SpiroNose®, a device equipped with multiple sensors detecting volatile organic compounds (VOCs). A supervised classification of the measurements through partial least squares discriminant analysis (PLS-DA) of the eNose data was performed.
Results
During the study period, the patient experienced an episode of ACR, confirmed by biopsy, and was treated with corticosteroids. Subsequently, she developed bacterial pneumonia as a complication of the treatment. The eNose successfully differentiated the breathprints during stable periods from those recorded during episodes of ACR and infection. Interestingly, even after treatment of ACR, the breathprint still indicated similarity to the ACR episode, suggesting potential for early detection of ongoing inflammation or recovery phases.
Discussion
The findings indicate that eNose technology could be a valuable non-invasive method for monitoring lung transplant recipients, potentially reducing the need for invasive procedures like biopsies. The eNose may offer additional clinical insight beyond standard lung function tests by distinguishing between different causes of lung function decline. Although this case study provides a promising proof of principle, larger studies are necessary to confirm the diagnostic accuracy and specificity of eNose technology in differentiating complications post-transplantation.
This research highlights the potential of eNose technology to improve patient outcomes by facilitating early diagnosis and tailored treatment interventions in lung transplant care.
